Thanks to the development of antiretroviral agents to control HIV replication, HIV infection has turned from a fatal disease into a treatable chronic infection. The present work collects the opinions of several experts on the efficacy and safety of recently approved second generation of integrase inhibitors and, in particular, on the role of this new class of drugs in antiretroviral therapy. The availability of new therapeutic options represents an opportunity to ameliorate the efficacy of cART in controlling HIV replication also within viral reservoirs. The personalization of the treatment driven mainly by the management of comorbidities, HIV-HCV co-infections and aging, will be easier with antiretroviral drugs without drug-drug interactions and with a better toxicity and tolerability profile. Future assessment of economic impact for the introduction of new innovative drugs in the field of antiretroviral therapy will likely need some degree of adjustment of the evaluation criteria of costs and benefit which are currently based almost exclusively on morbidity and mortality.

An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project

CALCAGNO, Andrea;DI PERRI, Giovanni;BONORA, Stefano;
2015-01-01

Abstract

Thanks to the development of antiretroviral agents to control HIV replication, HIV infection has turned from a fatal disease into a treatable chronic infection. The present work collects the opinions of several experts on the efficacy and safety of recently approved second generation of integrase inhibitors and, in particular, on the role of this new class of drugs in antiretroviral therapy. The availability of new therapeutic options represents an opportunity to ameliorate the efficacy of cART in controlling HIV replication also within viral reservoirs. The personalization of the treatment driven mainly by the management of comorbidities, HIV-HCV co-infections and aging, will be easier with antiretroviral drugs without drug-drug interactions and with a better toxicity and tolerability profile. Future assessment of economic impact for the introduction of new innovative drugs in the field of antiretroviral therapy will likely need some degree of adjustment of the evaluation criteria of costs and benefit which are currently based almost exclusively on morbidity and mortality.
2015
38
4
443
490
HAART; HIV; Integrase Inhibitors; PEP; PrEP
Andreoni, Massimo; Marcotullio, Simone; Puro, Vincenzo; De Carli, Gabriella; Tambussi, Giuseppe; Nozza, Silvia; Gori, Andrea; Rusconi, Stefano; Santoro, Maria Mercedes; Clementi, Massimo; Perno, Carlo Federico; d'Arminio Monforte, Antonella; Maggiolo, Franco; Castagna, Antonella; De Luca, Andrea; Galli, Massimo; Giacomelli, Andrea; Borderi, Marco; Guaraldi, Giovanni; Calcagno, Andrea; Di Perri, Giovanni; Bonora, Stefano; Mussini, Cristina; Di Biagio, Antonio; Puoti, Massimo; Bruno, Raffaele; Zuccaro, Valentina; Antinori, Andrea; Cinque, Paola; Croce, Davide; Restelli, Umberto; Rizzardini, Giuliano; Lazzarin, Adriano
File in questo prodotto:
File Dimensione Formato  
INSTI next aim Andreoni 2015.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 812.55 kB
Formato Adobe PDF
812.55 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1539591
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 10
social impact